Efficacy and safety of high-dose dexamethasone-based regimens in the newly diagnosed multiple myeloma patients with renal impairment / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 567-569, 2009.
Artículo
en Chino
| WPRIM
| ID: wpr-301650
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of high-dose dexamethasone-based regiments in newly diagnosed multiple myeloma patients with renal impairment.</p><p><b>METHODS</b>The clinical data of 22 patients with newly diagnosed multiple myeloma patients with renal impairment who received high-dose dexamethasone-based regiments from August 2006 to August 2008 in Peking Union Medical College Hospital were retrospectively reviewed.</p><p><b>RESULTS</b>After receiving a median 4 cycles of high-dose dexamethasone-based regiments, renal impairment was reversed in 7 patients (31.8%) with a median time to reversal of 31 days. Sixteen patients (72.7%) achieved overall response, including 7 patients (31.8%) had complete remission / near complete remission. The grade 3 or 4 adverse events included neutropenia (13.6%), infections (22.7%), peripheral neuropathy (9.1%), and ileus (4.5%).</p><p><b>CONCLUSION</b>The high-dose dexamethasone-based regiments are safe and effective for newly diagnosed multiple myeloma patients with renal impairment.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Dexametasona
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Estudios Retrospectivos
/
Resultado del Tratamiento
/
Usos Terapéuticos
/
Quimioterapia
/
Insuficiencia Renal
/
Mieloma Múltiple
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Acta Academiae Medicinae Sinicae
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS